^
    Back
    Association details:
    Biomarker:FLT3-ITD mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:bortezomib (Proteasome inhibitor) +
    Visudyne (verteporfin) (Reactive oxygen species stimulant, Photosensitizer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    FEBS Open Bio
    Title:

    Inhibition of the proteasome and proteaphagy enhances apoptosis in FLT3-ITD-driven acute myeloid leukemia

    Published date:
    08/15/2020
    Excerpt:
    Cooperative effects observed with the double Bz/VT treatment were statistically significant in MOLM‐14 cells but not in OCI‐AML3 (Fig. 5E,F). Taken together, our results show that the inhibition of both proteolytic pathways markedly enhances apoptosis levels in MOLM‐14 that express FLT3‐ITD (Fig. 6) but not in OCI‐AML3 that express WT FLT3.
    DOI:
    https://doi.org/10.1002/2211-5463.12950